Datapoint: FDA Approves Pfizer’s Hemophilia B Treatment
The FDA on April 26 approved Pfizer Inc.’s Beqvez (fidanacogene elaparvovec-dzkt) as a prophylactic treatment for adults with moderate to severe hemophilia B. Beqvez could become the new standard of care for hemophilia B, since it can prevent serious bleeding for up to three years after one dose is administered. Per Pfizer’s press release on the approval, the current standard of care “requires regular intravenous infusions…often administered multiple times a week or multiple times a month.” Pfizer will price a single course of Beqvez at $3.5 million before patient assistance and rebates, according to press reports. Norstella’s Evaluate Pharma projects the drug will net $57 million in global sales this year, following its July launch, growing to $378 million by 2030.
